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EDITORIAL
Mechanisms and clinical importance of hypertriglyceridemia in
the nephrotic syndrome
Hyperlipidemia is a cardinal feature of the nephrotic in vivo kinetic analysis, initially found that elevated tri-
syndrome and is characterized primarily by increased glyceride levels in nephrotic rats were not the result of
circulating levels of cholesterol-rich and triglyceride-rich increased triglyceride synthesis. Importantly, these results
lipoproteins that contain apolipoprotein (apo) B [1]. To are consistent with those found previously in nephrotic
date, most of the research has focused on the mechanism patients [5] and provide additional evidence that increased
and treatment of elevated low-density lipoprotein (LDL) VLDL levels in nephrotic syndrome are caused by de-
cholesterol associated with nephrotic syndrome because creased catabolism rather than increased synthesis. More-
of the recognized link between elevated LDL cholesterol over, these results arguably provide validation of the rat
and atherosclerosis. Less well studied, however, are the model for the study of lipoprotein alterations in the ne-
mechanisms responsible for increased triglyceride-rich phrotic syndrome. In the same experiment Shearer et al
lipoproteins in the nephrotic syndrome. Elaboration of also found that increased triglyceride synthesis was not
such mechanisms has potential clinical significance for at responsible for the modestly elevated triglycerides in NAR.
least two reasons. First, triglyceride-rich, apo B–contain- At least two factors may contribute to reduced VLDL
ing lipoproteins, such as very-low-density lipoprotein clearance in nephrotic syndrome. First, nephrotic syn-
(VLDL), may have atherogenic properties and increase drome may be associated with a reduction in lipoprotein
the risk of coronary events [2]. Second, triglyceride-rich lipase (LPL), the endothelial surface enzyme to which
lipoproteins may be important in the pathogenesis of renal triglyceride-rich lipoproteins bind in order to undergo
injury and may contribute to the progression of renal lipolysis and clearance [7]. Second, the triglyceride-rich
disease. Indeed, Samuelsson et al have reported a strong VLDL particle characteristic of nephrotic syndrome may
correlation between triglyceride-rich, apo B–containing have defective binding to the endothelium. Using the
lipoproteins and the rate of progression of renal insuffi- Langendorff isolated perfused heart preparation, in which
ciency in patients with chronic renal disease [3]. Obese perfusate triglyceride levels could be controlled, Shearer
Zucker rats, an experimental model of noninsulin-depen- et al demonstrated reduced chylomicron clearance by
dent diabetes mellitus, have profoundly elevated triglyc- hearts from nephrotic rats and NAR, both of which have
erides and develop progressive renal disease at a rela- reduced LPL activity (chylomicrons, triglyceride-rich lipo-
tively young age [4]. proteins cleared by mechanisms similar to those of VLDL
It has previously been shown that increased VLDL in clearance, were isolated from normal rats and used as
patients with nephrotic syndrome is caused primarily viable VLDL surrogates to study the rate of triglyceride
by decreased VLDL catabolism, rather than increased lipolysis because it is much easier to radiolabel triglycer-
VLDL synthesis [5]. In the current issue of Kidney Inter- ides in chylomicrons than in VLDL). Because NAR have
national, Shearer et al confirm and extend this observa- much lower triglyceride levels than nephrotic rats, de-
tion in a study designed to investigate the mechanism spite similarly reduced LPL activity, the results of the
of increased VLDL triglycerides in rats with nephrotic isolated heart experiments suggested that reduced LPL
syndrome [6]. A unique aspect of their study was the activity alone might not be sufficient to cause the mark-
use of Nagase analbuminemic rats (NAR) as “controls” edly elevated triglyceride levels in the nephrotic rats.
for the nephrotic rats. NAR are deficient in serum albu- Thus, the authors investigated whether an alternate
min and thus have reduced plasma oncotic pressure like mechanism, that is, abnormal binding of VLDL to the
nephrotic rats. By contrast, NAR have only modestly endothelium, might also contribute to impaired VLDL
elevated triglycerides and are not proteinuric. clearance.
In a well-designed series of experiments involving sev- Using rat and bovine endothelial cells cultured in the
eral complementary approaches, Shearer et al, using an presence of controlled levels of purified LPL, the authors
determined that VLDL isolated from nephrotic rats, but
not from NAR, had deficient endothelial binding. It isKey words: lipoproteins, VLDL, apolipoprotein E, proteinuria, clear-
ance, triglycerides. important to recognize that optimal binding of VLDL
to the endothelium appears to also require the presenceÓ 2001 by the International Society of Nephrology
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of a so-called “high-affinity” form of apo E in the VLDL as an angiotensin-converting enzyme inhibitor or angio-
particle. Apo E is donated to VLDL by high-density tensin receptor blocker to reduce proteinuria also ap-
lipoprotein (HDL), and the content of high-affinity pears to be important because proteinuria, through some
apo E in the VLDL particle is apparently dependent on unknown mechanism, appears to cause HDL abnormali-
its triglyceride content [8]. Triglyceride-rich VLDL, as ties that facilitate accumulation of triglyceride-rich VLDL.
occurs in nephrotic syndrome, may lack high-affinity In conclusion, the results of the study by Shearer et
apo E and thus display deficient endothelial binding. al in nephrotic rats are consistent with previous clinical
Although Shearer et al did not directly determine if studies and indicate that accumulation of triglyceride-
VLDL of nephrotic rats was deficient in high-affinity rich lipoproteins in the nephrotic syndrome results from
apo E, they did demonstrate that the VLDL was triglyc- defective clearance of these particles. Impaired clearance
eride enriched, compared to VLDL from normal control of triglyceride-rich VLDL may be the result of two fac-
rats or NAR. Moreover, they found that HDL of ne- tors: (1) reduced endothelial LPL activity, and, perhaps
phrotic rats was deficient in apo E, a potentially impor- more important, (2) alterations in the triglyceride and
tant new finding. In vitro endothelial binding of VLDL apo E content of VLDL particles that impair endothelial
from nephrotic rats was substantially improved by pre- binding and subsequent lipolysis. The results of the pres-
incubating the VLDL with HDL isolated from either ent study indicate that proteinuria, and not hypo-
normal, control rats, or NAR, each of which had higher albuminemia, associated with the nephrotic syndrome
apo E content than nephrotic HDL. Conversely, endo- appears in some way to cause reduced apo E in HDL, the
thelial binding of VLDL from normal rats was impaired particles that contribute apo E to VLDL. Therapeutic
by pre-incubation of the VLDL with HDL from ne- strategies to reduce triglyceride-rich lipoproteins in the
phrotic rats. As a counterpart to the in vitro studies,
nephrotic syndrome, therefore, might include agents that
infusion of HDL isolated from normal, control rats im-
reduce triglycerides, elevate LPL activity, and correct
proved (although it did not normalize) chylomicron
HDL abnormalities.
clearance in nephrotic rats. Collectively, these results
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